Company intelligence / Profile preview

BioHealing

Czech Republicbiohealingorthopedics.com ↗

Ownership: Private
Development stage: Commercial

Overview

BioHealing has demonstrated strong clinical results with its lead product, AMNIODERM®, showing up to 65% of non-healing wounds healed within 12 weeks. The CE certification process is ongoing for the next-generation product, AMNIODERM+®. Retrospective-prospective clinical trials have been conducted with positive outcomes.

Therapeutic areas: Endocrinology
Modalities: Medical deviceBiologic (perinatal tissue-derived)Regenerative medicine product
Industry: Consumable Medical Devices

Drug pipeline

2 assets

Tesla MedBed Generator

Commercial

Indications: Pain, Blood circulation

1 more asset in the full pipeline.

Request access →

Partnerships

Zentiva – exclusive license/distribution agreements for several European countries for DFU application of AMNIODERM®TDS – exclusive license/distribution agreement for Jordan

Beyond the preview

Go deeper on BioHealing.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioHealing.

Explore the full profile